Galena Biopharma, a developer of targeted oncology treatments that address major unmet needs in cancer care, reported today it will be presenting at the Oppenheimer 24th Annual Healthcare Conference in New York City. The company's President and CEO, Mark J. Anh, PhD, will be presenting a corporate update at the conference, taking place next week on Tuesday, December 10, 2013 at 10:55 am EST at the Crowne Plaza Hotel.
The presentation will be webcast, available in the Investors section at: galenabiopharma.com.
Galena Biopharma currently has a strong clinical pipeline in place. The primary therapeutic solution the company has in development is NeuVax, a cancer immunotherapy that takes advantage of the immune system's power to locate and destroy HER2-presenting cells. The HER2 is a well-established target for clinical action against breast carcinoma. It is injected into the body to destroy these cells that are currently present as well as act as an inhibitor against future appearances of these cells. The immunotherapy is currently in Phase III testing for FDA approval against breast cancer recurrence.
The company is also developing Folate Binding Protein-E39, a targeted vaccine aimed at preventing the recurrence of ovarian, endometrial, and breast cancers. It is currently in Phase I testing of FDA approval.
The company released in October Abstral®. That is a sublingual (under the tongue) fentanyl tablet indicated for the management of breakthrough pain in patients with cancer, 18 years of age and older, who are already receiving, and who are tolerant to, opioid therapy for their persistent baseline cancer pain.
MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.missionir.com